

# Abd A. Tahrani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1934363/publications.pdf>

Version: 2024-02-01

179  
papers

5,011  
citations

109321  
35  
h-index

114465  
63  
g-index

187  
all docs

187  
docs citations

187  
times ranked

6295  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity Without Metabolic Abnormality and Incident CKD: A Population-Based British Cohort Study. American Journal of Kidney Diseases, 2022, 79, 24-35.e1.	1.9	21
2	Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). Journal of Neurology, 2022, 269, 1945-1956.	3.6	17
3	Exercise in Obesityâ€”the Role of Technology in Health Services: Can This Approach Work?. Current Obesity Reports, 2022, 11, 93-106.	8.4	11
4	Oral 11Î²-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial. European Journal of Endocrinology, 2022, 186, 441-455.	3.7	12
5	Clinical Use of the Edmonton Obesity Staging System for the Assessment of Weight Management Outcomes in People with Class 3 Obesity. Nutrients, 2022, 14, 967.	4.1	5
6	Benefits of weight loss of 10% or more in patients with overweight or obesity: A review. Obesity, 2022, 30, 802-840.	3.0	41
7	The Impact of the COVID-19 Pandemic on Mobility Trends and the Associated Rise in Population-Level Physical Inactivity: Insights From International Mobile Phone and National Survey Data. Frontiers in Sports and Active Living, 2022, 4, 773742.	1.8	8
8	How to manage weight loss in women with obesity and PCOS seeking fertility?. Clinical Endocrinology, 2022, , .	2.4	7
9	The effect of intranasal insulin on appetite and mood in women with and without obesity: an experimental medicine study. International Journal of Obesity, 2022, 46, 1319-1327.	3.4	9
10	Global variations in preoperative practices concerning patients seeking primary bariatric and metabolic surgery (PACT Study): A survey of 634 bariatric healthcare professionals. International Journal of Obesity, 2022, 46, 1341-1350.	3.4	5
11	Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee. Advances in Therapy, 2022, 39, 3019-3030.	2.9	3
12	Managing idiopathic intracranial hypertension in pregnancy: practical advice. Practical Neurology, 2022, 22, 295-300.	1.1	17
13	Safety of Bariatric Surgery in 65-Year-Old Patients During the COVID-19 Pandemic. Obesity Surgery, 2022, 32, 1-13.	2.1	4
14	052â€¦ How much weight loss is required to reduce intracranial pressure in idiopathic intracranial hypertension?. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A116.4-A117.	1.9	0
15	Sleep behaviours and associated habits and the progression of pre-diabetes to type 2 diabetes mellitus in adults: A systematic review and meta-analysis. Diabetes and Vascular Disease Research, 2022, 19, 147916412210888.	2.0	7
16	Sodiumâ€”glucose coâ€”transporterâ€”2 inhibitors and susceptibility to <scp>COVID</scp>â€”19: A populationâ€”based retrospective cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 263-269.	4.4	34
17	The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study. Diabetes Care, 2021, 44, 116-124.	8.6	13
18	Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 7-9.	11.4	58

#	ARTICLE	IF	CITATIONS
19	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1255-1268.	3.6	23
20	Metabolic surgery: A clinical update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 63-83.	4.4	19
21	The impact of sleep disorders on microvascular complications in patients with type 2 diabetes (SLEEP) Tj ETQq1 1 0.784314 rgBT /Ov Studies, 2021, 7, 80.	1.2	2
22	The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension. <i>Neurology: Clinical Practice</i> , 2021, 11, e504-e507.	1.6	38
23	The Health Economic Evaluation of Bariatric Surgery Versus a Community Weight Management Intervention Analysis from the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT). <i>Life</i> , 2021, 11, 409.	2.4	6
24	Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. <i>JAMA Neurology</i> , 2021, 78, 678.	9.0	86
25	Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?. <i>Metabolism Open</i> , 2021, 10, 100082.	2.9	1
26	30-Day Morbidity and Mortality of Bariatric Surgery During the COVID-19 Pandemic: a Multinational Cohort Study of 7704 Patients from 42 Countries. <i>Obesity Surgery</i> , 2021, 31, 4272-4288.	2.1	34
27	30-Day morbidity and mortality of bariatric metabolic surgery in adolescence during the COVID-19 pandemic â€” The GENEVA study. <i>Pediatric Obesity</i> , 2021, 16, e12832.	2.8	16
28	Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1310-1316.	1.2	15
29	Safety and feasibility of revisional bariatric surgery following Laparoscopic Adjustable Gastric Band â€” Outcomes from a large UK private practice. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 381-386.	1.8	1
30	Effect of COVID-19 pandemic on global Bariatric surgery PRACTiceS â€” The COBRAS study. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 395-401.	1.8	21
31	Social Deprivation and Incident Diabetes-Related Foot Disease in Patients With Type 2 Diabetes: A Population-Based Cohort Study. <i>Diabetes Care</i> , 2021, 44, 731-739.	8.6	19
32	Post-bariatric surgery nutritional follow-up in primary care: a population-based cohort study. <i>British Journal of General Practice</i> , 2021, 71, e441-e449.	1.4	9
33	Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study. <i>Diabetes Care</i> , 2021, 44, 2758-2766.	8.6	4
34	Exploring the awareness, attitudes, and actions (AAA) of UK adults at high risk of severe illness from COVID-19. <i>PLoS ONE</i> , 2021, 16, e0259376.	2.5	2
35	Obstructive sleep apnoea and 12-month weight loss in adults with class 3 obesity attending a multidisciplinary weight management program. <i>BMC Endocrine Disorders</i> , 2021, 21, 227.	2.2	4
36	The clinical profile and associated mortality in people with and without diabetes with Coronavirus disease 2019 on admission to acute hospital services. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, , e00309.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002480.	2.8	31
38	The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis. <i>Sleep and Breathing</i> , 2020, 24, 339-350.	1.7	55
39	The effect of Ramadan fasting on cardiovascular events and risk factors in patients with type 2 diabetes: A systematic review. <i>Diabetes Research and Clinical Practice</i> , 2020, 159, 107918.	2.8	15
40	Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 870-871.	11.4	3
41	COVID-19 and obesity: an opportunity for change. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882094974.	3.2	4
42	Developing Integrated Clinical Pathways for the Management of Clinically Severe Adult Obesity: a Critique of NHS England Policy. <i>Current Obesity Reports</i> , 2020, 9, 530-543.	8.4	35
43	The implementation of a physical activity intervention in adults with Obstructive Sleep Apnoea over the age of 50 years: a feasibility uncontrolled clinical trial. <i>BMC Sports Science, Medicine and Rehabilitation</i> , 2020, 12, 46.	1.7	4
44	Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study. <i>Diabetes Care</i> , 2020, 43, 1868-1877.	8.6	45
45	COVID-19 and obesity—lack of clarity, guidance, and implications for care. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 474-475.	11.4	52
46	Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. <i>Drugs</i> , 2020, 80, 467-475.	10.9	67
47	The relationship between obstructive sleep apnoea and quality of life in women with polycystic ovary syndrome: a cross-sectional study. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882090668.	3.2	9
48	Weight loss during medical weight management does not predict weight loss after bariatric surgery: a retrospective cohort study. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1723-1730.	1.2	8
49	Evidence-based prescribing of diabetes medications: are we getting closer?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 176-177.	11.4	3
50	Impact of bariatric surgery on cardiovascular outcomes and mortality: a population-based cohort study. <i>British Journal of Surgery</i> , 2020, 107, 432-442.	0.3	59
51	The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 447-455.	11.4	77
52	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2985-2996.	4.3	14
53	Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: A population-based cohort study, systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107401.	2.3	22
54	lDGLira: combining efficacy, durability, and convenience?. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 584-585.	11.4	0

#	ARTICLE	IF	CITATIONS
55	The Relationship between Disturbed Sleep, OSAS, and Metabolic Diseases. Journal of Diabetes Research, 2019, 2019, 1-2.	2.3	4
56	Risk of Incident Obstructive Sleep Apnea Among Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 954-963.	8.6	63
57	Reduced physical activity in young and older adults: metabolic and musculoskeletal implications. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881988882.	3.2	132
58	Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort. Clinical Endocrinology, 2019, 90, 145-154.	2.4	42
59	MECHANISMS OF ENDOCRINOLOGY: Mechanisms of disease: the endocrinology of obstructive sleep apnoea. European Journal of Endocrinology, 2019, 180, R91-R125.	3.7	24
60	Hypoglycaemia is associated with increased risk of fractures in patients with type 2 diabetes mellitus: a cohort study. European Journal of Endocrinology, 2019, 180, 51-58.	3.7	27
61	Increased risk of obstructive sleep apnoea in women with polycystic ovary syndrome: a population-based cohort study. European Journal of Endocrinology, 2019, 180, 265-272.	3.7	40
62	Once-weekly GLP-1R agonists: moving the goal posts. Lancet Diabetes and Endocrinology, the, 2018, 6, 260-261.	11.4	2
63	The association between obstructive sleep apnea and metabolic abnormalities in women with polycystic ovary syndrome: a systematic review and meta-analysis. Sleep, 2018, 41, .	1.1	26
64	Roux-en-Y Gastric Bypass: Does the Direction of Staples Matter?. Obesity Surgery, 2018, 28, 2868-2873.	2.1	3
65	Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project. Diabetes Therapy, 2018, 9, 839-849.	2.5	7
66	Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: <scp>A</scp> longitudinal analysis. Diabetes, Obesity and Metabolism, 2018, 20, 745-748.	4.4	12
67	Initiation of dapagliflozin and treatment-emergent fractures. Diabetes, Obesity and Metabolism, 2018, 20, 1070-1074.	4.4	33
68	Binge eating disorder and night eating syndrome in adults with type 2 diabetes: a systematic review. Journal of Eating Disorders, 2018, 6, 36.	2.7	45
69	Ethnic differences in the pathogenesis of obstructive sleep apnoea: <scp>E</scp>xploring non-anatomical factors. Respiriology, 2017, 22, 847-848.	2.3	2
70	Systematic Review and Meta-Analysis of Outcomes After Revisional Bariatric Surgery Following a Failed Adjustable Gastric Band. Obesity Surgery, 2017, 27, 2522-2536.	2.1	47
71	Obstructive sleep apnoea in diabetes: Does it matter?. Diabetes and Vascular Disease Research, 2017, 14, 454-462.	2.0	39
72	Novel therapies in type 2 diabetes: insulin resistance. Practical Diabetes, 2017, 34, 161.	0.3	10

#	ARTICLE	IF	CITATIONS
73	Obstructive Sleep Apnea and Retinopathy in Patients with Type 2 Diabetes. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 892-900.	5.6	73
74	Obstructive sleep apnoea and polycystic ovary syndrome: A comprehensive review of clinical interactions and underlying pathophysiology. Clinical Endocrinology, 2017, 87, 313-319.	2.4	46
75	Prevalence of undiagnosed type 2 diabetes in patients admitted with acute coronary syndrome: the utility of easily reproducible screening methods. BMC Endocrine Disorders, 2017, 17, 3.	2.2	4
76	Prevalence and Associations of Obstructive Sleep Apnea in South Asians and White Europeans with Type 2 Diabetes: A Cross-Sectional Study. Journal of Clinical Sleep Medicine, 2017, 13, 583-589.	2.6	36
77	Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 419-434.	2.4	87
78	Peripheral and Autonomic Neuropathy in South Asians and White Caucasians with Type 2 Diabetes Mellitus: Possible Explanations for Epidemiological Differences. Journal of Diabetes Research, 2017, 2017, 1-10.	2.3	18
79	Diabetic Neuropathy: Current Status and Future Prospects. Journal of Diabetes Research, 2017, 2017, 1-2.	2.3	12
80	Call for Submissions 2018. European Endocrinology, 2017, 13, 49.	1.5	0
81	Letter from the Editor-in-Chief. European Endocrinology, 2017, 13, 12.	1.5	0
82	The impact of bariatric surgery on estimated glomerular filtration rate in patients with type 2 diabetes: a retrospective cohort study. Surgery for Obesity and Related Diseases, 2016, 12, 1883-1889.	1.2	18
83	The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1315-1320.	2.3	33
84	Foot insensitivity is associated with renal function decline in patients with type 2 diabetes: a cohort study. BMC Endocrine Disorders, 2016, 16, 64.	2.2	6
85	Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 207, 220-226.	1.1	61
86	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology, 2016, 12, 566-592.	9.6	292
87	Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes and Endocrinology, the, 2016, 4, 350-359.	11.4	80
88	The impact of bariatric surgery on retinopathy in patients with type 2 diabetes: a retrospective cohort study. Surgery for Obesity and Related Diseases, 2016, 12, 606-612.	1.2	40
89	Obstructive sleep apnoea: a diabetologist's perspective. British Journal of Diabetes, 2016, 16, 107.	0.2	2
90	Obstructive sleep apnea in patients with diabetes: implications for clinical practice. Diabetes Management, 2015, 5, 511-523.	0.5	1

#	ARTICLE	IF	CITATIONS
91	The role of <sc>GLP</sc>1 receptor agonists as weight loss agents in patients with and without type 2 diabetes. Practical Diabetes, 2015, 32, 297.	0.3	16
92	Obstructive Sleep Apnea and Diabetic Microvascular Complications. , 2015, , 213-224.		0
93	Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes, Obesity and Metabolism, 2015, 17, 319-334.	4.4	52
94	Obstructive Sleep Apnoea and Vascular Disease in Patients with Type 2 Diabetes. European Endocrinology, 2015, 11, 81.	1.5	17
95	Obstructive Sleep Apnoea and Vascular Disease in Patients with Type 2 Diabetes. US Endocrinology, 2015, 11, 110.	0.3	0
96	Mechanisms Underlying Cardiovascular Disease in Diabetes Mellitus. MD Conference Express, 2015, 15, 23-24.	0.0	0
97	Oxidative Stress, Inflammation and Endothelial Dysfunction: The Link Between Obstructive Sleep Apnoea and Vascular Disease in Type 2 Diabetes. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 149-171.	0.4	3
98	SGLT-2 inhibitors as second-line therapy in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2014, 2, 678-679.	11.4	6
99	Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. Diabetologia, 2014, 57, 1249-1256.	6.3	60
100	In-patient diabetes care: the impact of diabetes outreach team on long-term glycaemic control. International Journal of Clinical Practice, 2014, 68, 1333-1337.	1.7	9
101	Comment on Guest et al. Clinical Outcomes and Cost-effectiveness of Continuous Positive Airway Pressure to Manage Obstructive Sleep Apnea in Patients With Type 2 Diabetes in the U.K. Diabetes Care 2014;37:1263-1271. Diabetes Care, 2014, 37, e200-e201.	8.6	1
102	Cardiac autonomic neuropathy in patients with diabetes mellitus. World Journal of Diabetes, 2014, 5, 17.	3.5	239
103	SGLT inhibitors in management of diabetes. Lancet Diabetes and Endocrinology,the, 2013, 1, 140-151.	11.4	268
104	Advances in Pharmaceutical Options and Current Clinical Trials for the Treatment of Painful Diabetic Polyneuropathy. , 2013, , 121-138.		1
105	Obstructive sleep apnoea; a rare cause of pseudophaeochromocytoma. QJM - Monthly Journal of the Association of Physicians, 2013, 106, 1133-1136.	0.5	6
106	Obstructive sleep apnoea and diabetes. Current Opinion in Pulmonary Medicine, 2013, 19, 631-638.	2.6	46
107	Obstructive Sleep Apnea and Diabetic Nephropathy. Diabetes Care, 2013, 36, 3718-3725.	8.6	102
108	11 $\beta$ -Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. Journal of Clinical Investigation, 2013, 123, 3051-3060.	8.2	110



#	ARTICLE	IF	CITATIONS
109	Obstructive Sleep Apnea and Diabetic Neuropathy. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 434-441.	5.6	160
110	Cutaneous Structural and Biochemical Correlates of Foot Complications in High-Risk Diabetes. Diabetes Care, 2012, 35, 1913-1918.	8.6	19
111	Insulin degludec: a new ultra-longacting insulin. Lancet, The, 2012, 379, 1465-1467.	13.7	11
112	OP11: Metabolic and vascular determinants of increased left ventricular torsion in patients with type 2 diabetes mellitus. Diabetes and Metabolism, 2012, 38, S102.	2.9	0
113	Limitations of glycosylated haemoglobin (HbA <sub>1c</sub> ) in diabetes screening. Practical Diabetes, 2012, 29, 29-31.	0.3	1
114	315* Cardiac autonomic neuropathy (CAN) is more likely to occur in cystic fibrosis (CF) patients with or without diabetes than in patients with type 1 diabetes (T1DM). Journal of Cystic Fibrosis, 2011, 10, S80.	0.7	0
115	316* Cardiac autonomic neuropathy (CAN) is related to lung function in adults with cystic fibrosis related diabetes (CFRD). Journal of Cystic Fibrosis, 2011, 10, S80.	0.7	0
116	Management of type 2 diabetes: new and future developments in treatment. Lancet, The, 2011, 378, 182-197.	13.7	459
117	SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment. Review of Diabetic Studies, 2011, 8, 348-354.	1.3	25
118	Abnormal left ventricular torsion and cardiac autonomic dysfunction in subjects with type 1 diabetes mellitus. Metabolism: Clinical and Experimental, 2011, 60, 1115-1121.	3.4	28
119	Effects of a synthetic retinoid on skin structure, matrix metalloproteinases, and procollagen in healthy and high-risk subjects with diabetes. Journal of Diabetes and Its Complications, 2011, 25, 398-404.	2.3	16
120	Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes/Metabolism Research and Reviews, 2011, 27, 665-677.	4.0	76
121	Predicting dysglycaemia in patients under investigation for acute coronary syndrome. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 231-236.	0.5	5
122	Awareness of Obesity and Diabetes: A Survey of a Subset of British Male Drivers. American Journal of Men's Health, 2011, 5, 30-37.	1.6	19
123	OSA Associated with Diabetes Complications. MD Conference Express, 2011, 11, 30-31.	0.0	0
124	Chapter 10 Challenges to good diabetes care. , 2011, , .		0
125	Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Therapy, 2010, 1, 45-56.	2.5	28
126	Glycaemic control in type 2 diabetes: Targets and new therapies. , 2010, 125, 328-361.		155



#	ARTICLE	IF	CITATIONS
127	Liraglutide, a new diabetes treatment approved by NICE. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 377-378.	0.2	0
128	The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. International Journal of Clinical Practice, 2010, 64, 351-355.	1.7	72
129	Emerging treatment options for type 2 diabetes. British Journal of Clinical Pharmacology, 2010, 70, 631-644.	2.4	44
130	The management of hyponatraemia at two district general hospitals in the UK. Journal of Evaluation in Clinical Practice, 2010, 16, 1353-1356.	1.8	7
131	Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Preference and Adherence, 2010, 4, 313.	1.8	13
132	A high prevalence of cardiac autonomic dysfunction in CF patients with and without CF-related diabetes (CFRD). Journal of Cystic Fibrosis, 2010, 9, S83.	0.7	0
133	Emerging drugs for diabetic neuropathy. Expert Opinion on Emerging Drugs, 2010, 15, 661-683.	2.4	38
134	Obstructive Sleep Apnoea and Type 2 Diabetes. European Endocrinology, 2010, 10, 43.	1.5	13
135	DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine, 2009, 121, 70-100.	2.0	34
136	Drug evaluation: Vildagliptin-metformin single-tablet combination. Advances in Therapy, 2009, 26, 138-154.	2.9	25
137	Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Advances in Therapy, 2009, 26, 249-262.	2.9	81
138	Bariatric surgery: a cure for diabetes?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2009, 26, 356-358.	0.2	2
139	NICE gives rimonabant the green light. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 302-304.	0.2	0
140	Liraglutide: a new option in the management of type 2 diabetes. Future Prescriber, 2008, 9, 6-12.	0.1	2
141	Management of type 2 diabetes: the GLP-1 pathway. Future Prescriber, 2008, 9, 18-24.	0.1	3
142	Glargine in pregnant patients with Type 1 diabetes. Diabetic Medicine, 2008, 25, 111-112.	2.3	9
143	A patient with worsening mobility: A diagnostic challenge. European Journal of Internal Medicine, 2008, 19, 292-294.	2.2	7
144	Exenatide: incretin therapy for patients with Type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2008, 3, 671-690.	2.4	5

#	ARTICLE	IF	CITATIONS
145	Impact of practice size on delivery of diabetes care before and after the Quality and Outcomes Framework implementation. British Journal of General Practice, 2008, 58, 576-579.	1.4	14
146	Controlling blood pressure in type-2 diabetes. Independent Nurse, 2008, 2008, .	0.1	0
147	Medical image. An occult infection in the setting of diabetes mellitus. Multiple loculated shoulder abscesses. New Zealand Medical Journal, 2008, 121, 89-91.	0.5	0
148	Letter Regarding Article, "Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk". Circulation, 2007, 116, e339.	1.6	0
149	Optimizing diabetes care: perspectives from a practical view point. Journal of the Royal Society of Medicine, 2007, 100, 67-67.	2.0	1
150	An Unusual Cause of Severe Hypoglycaemia in Type 1 Diabetes Mellitus. Antepartum Pituitary Failure: A Case Report and Literature Review. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 136-138.	1.2	8
151	Grave's Eye Disease Developing Following Radioiodine Treatment for Toxic Nodular Goitre. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 471-473.	1.2	8
152	Impaired glucose tolerance and the risk of ischaemic stroke: another focus. Age and Ageing, 2007, 36, 350-351.	1.6	0
153	The Long and Short of Metformin-Related Vitamin B12 Deficiency. Archives of Internal Medicine, 2007, 167, 729.	3.8	5
154	Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?. BMJ: British Medical Journal, 2007, 335, 508-512.	2.3	111
155	The Putative Link Between Glycemic Control and Cardiac Arrhythmias. Archives of Internal Medicine, 2007, 167, 1433.	3.8	3
156	A Caveat in the Management of Acute Gout. American Journal of Medicine, 2007, 120, e31.	1.5	1
157	Optimizing diabetes care: perspectives from a practical view point. Journal of the Royal Society of Medicine, 2007, 100, 67-67.	2.0	2
158	The use of glargine in pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2007, 114, 1178-1179.	2.3	1
159	A case of multi-organ failure. International Journal of Clinical Practice, 2007, 61, 514-516.	1.7	5
160	Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. International Journal of Clinical Practice, 2007, 61, 329-335.	1.7	15
161	Diabetes mellitus and cardiovascular risk factors: more insights revisited. International Journal of Clinical Practice, 2007, 61, 1055-1056.	1.7	0
162	Diabetes care and the new GMS contract: the evidence for a whole county. British Journal of General Practice, 2007, 57, 483-5.	1.4	35

#	ARTICLE	IF	CITATIONS
163	Colchicine: time to rethink. New Zealand Medical Journal, 2007, 120, U2429.	0.5	8
164	Resolution of diabetes in type 2 diabetic patient treated with IFN-?? and ribavirin for hepatitis C. European Journal of Gastroenterology and Hepatology, 2006, 18, 291-293.	1.6	17
165	The development of non-insulin-dependent diabetes after total body irradiation and bone marrow transplantation in adolescence: a case report and literature review. Pediatric Diabetes, 2006, 7, 173-175.	2.9	7
166	TREATING HYPERTENSION IN OLDER PEOPLE: PRACTICAL IMPLICATIONS OF ACHIEVING TARGETS. Journal of the American Geriatrics Society, 2006, 54, 1972-1972.	2.6	1
167	Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus. International Journal of Clinical Practice, 2006, 60, 1515-1515.	1.7	0
168	Caveats in treating thyroid disease: practical implications. Journal of the Royal Society of Medicine, 2006, 99, 582-583.	2.0	2
169	Carbimazole therapy in the setting of end-stage renal disease and haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 2318-2319.	0.7	5
170	A Diagnostic Dilemma in Diagnosing and Managing an Incidental Pheochromocytoma. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 204-207.	1.2	3
171	Changing perspectives of general medicine on general practice. Journal of the Royal Society of Medicine, 2006, 99, 168-169.	2.0	0
172	Pay-for-Performance Programs in the United Kingdom. New England Journal of Medicine, 2006, 355, 1832-1833.	27.0	6
173	Saxagliptin a New Second Line Therapy After Metformin for the Treatment of Type 2 Diabetes. Clinical Medicine Reviews in Vascular Health, 0, 2, .	3.0	0
174	Meal size and frequency influences metabolic endotoxaemia and inflammatory risk but has no effect on diet induced thermogenesis in either lean or obese subjects. Endocrine Abstracts, 0, , .	0.0	0
175	Treatment of vitamin D deficiency in primary hyperparathyroidism (PHPT) with different vitamin D preparations.. Endocrine Abstracts, 0, , .	0.0	0
176	Baseline characteristics of patients presenting with primary hyperparathyroidism. Endocrine Abstracts, 0, , .	0.0	0
177	The use of ketogenic diet in a patient with post-prandial hyperinsulinemic hypoglycaemia after m Roux-en-Y Gastric Bypass surgery: a case study. Endocrine Abstracts, 0, , .	0.0	0
178	Risk of incident obstructive sleep apnoea in patients with type 1 diabetes: a population-based retrospective cohort study. Diabetologia, 0, , .	6.3	1
179	Diabetic Foot Risk Classification at the Time of Type 2 Diabetes Diagnosis and Subsequent Risk of Mortality: A Population-Based Cohort Study. Frontiers in Endocrinology, 0, 13, .	3.5	2